7Baggers
 Astria Therapeutics expands phase 3 HAE trial to European Union  Investing.com India Thu, 02 Oct 2025 12:25:59 GMT
 Astria Therapeutics stock price target raised to $20 at H.C. Wainwright  Investing.com Australia Thu, 18 Sep 2025 13:13:25 GMT
 astria (atxs) successfully completes star-0310 phase 1 trial  GuruFocus Wed, 17 Sep 2025 14:55:57 GMT
 ATXS: Cantor Fitzgerald Reiterates Overweight Rating with $49 Pr  GuruFocus Wed, 17 Sep 2025 14:43:53 GMT
 Astria Therapeutics (ATXS) Reports Promising Phase 1a Trial Resu  GuruFocus Wed, 17 Sep 2025 12:57:56 GMT
 Astria Therapeutics : Corporate Presentation  MarketScreener Wed, 17 Sep 2025 07:00:00 GMT
 Astria Bets On High-Stakes Drug Trials For Its Future  Finimize Tue, 16 Sep 2025 16:40:20 GMT
 astria therapeutics, inc. $atxs shares sold by redmile group llc  MarketBeat Sun, 07 Sep 2025 15:56:15 GMT
 astria therapeutics at cantor conference: strategic program insights by investing.com  Investing.com South Africa Fri, 05 Sep 2025 01:24:18 GMT
 Astria Therapeutics at Cantor Conference: Strategic Program Insights  Investing.com Thu, 04 Sep 2025 07:00:00 GMT
 astria therapeutics to present star-0310 phase 1a data at eadv congress  Investing.com Canada Thu, 04 Sep 2025 06:28:12 GMT
 International Business Times  FinancialContent Wed, 27 Aug 2025 07:00:00 GMT

Astria Therapeutics, Inc.
(NASDAQ:ATXS) 

ATXS stock logo

Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development fo...

Founded: 2008
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends